Limited ResearchCognitive

DNSP-11

Dopamine Neuron Stimulating Peptide-11

GDNF-Derived Peptide | Dopaminergic Neuroprotection

Half-life

Not well characterized

Chain length

11 amino acids

Reference frequency

1x daily (morning recommended)

Research overview

DoseGear research brief

DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson's disease research and biohacking communities focused on dopamine system health.

Mechanism of action

DNSP-11 acts on dopaminergic neurons through mechanisms distinct from full-length GDNF. Rather than binding to the canonical GFRalpha1/RET receptor complex, DNSP-11 appears to engage alternative signaling pathways to promote dopaminergic neuron survival, stimulate dopamine release, and protect against neurotoxin-induced damage. It enhances tyrosine hydroxylase expression (the rate-limiting enzyme in dopamine synthesis) and supports mitochondrial function in dopaminergic neurons.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Eleven-amino-acid peptide from the GDNF pro-domain.

What it is researched for

Dopaminergic-neuron protection and Parkinsonian animal models; its complete receptor mechanism is not established.

Research observation window

Cited rat-model work reports effects lasting multiple weeks after a single injection; the page summary does not give an exact interval.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

No sourced lyophilized-vial injectable protocol is listed for this profile.

Safety context

Reported side effects

Nasal irritation or mild burning sensation (intranasal route)
Injection site reactions such as redness or swelling (subcutaneous route)

Contraindications & cautions

Pregnancy or breastfeeding
Known peptide allergies
Very limited human safety data; use at own risk
Consult a physician before combining with dopaminergic medications

Scientific references

01
DNSP-11 Is a Novel GDNF Pro-Peptide That Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
Scientific citationDNSP-11 Is a Novel GDNF Pro-Peptide That Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease. Neuroscience Letters (2010).
02
Dopamine Neuron Stimulating Peptide-11 (DNSP-11): A Novel, Small Peptide That Provides Long-Term Protection in a Rat Model of Parkinson's Disease
Scientific citationDopamine Neuron Stimulating Peptide-11 (DNSP-11): A Novel, Small Peptide That Provides Long-Term Protection in a Rat Model of Parkinson's Disease. Neuropharmacology (2011).
03
DNSP-11 Induces Behavioral Recovery and Nigrostriatal Neurochemical Changes in a Unilateral 6-OHDA Rat Model of Parkinson's Disease
Scientific citationDNSP-11 Induces Behavioral Recovery and Nigrostriatal Neurochemical Changes in a Unilateral 6-OHDA Rat Model of Parkinson's Disease. Society for Neuroscience Abstract (2012).
04
Identification of Two Novel Peptides from the GDNF Pro-Domain That Bind to GFRalpha1
Scientific citationIdentification of Two Novel Peptides from the GDNF Pro-Domain That Bind to GFRalpha1. Analytical Biochemistry (2012).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Cognitive